Spyre Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
The exhibits filed or furnished as part of this Quarterly Report on Form 10-Q are set forth below.
| ExhibitNumber | Description | Form | File No | Date of Filing | ExhibitNo. | FiledHerewith |
|---|---|---|---|---|---|---|
| 2.1 | Agreement and Plan of Merger, dated June 22, 2023, by and among Aeglea BioTherapeutics, Inc. Aspen Merger Sub I, Inc., Sequoia Merger Sub II, LLC and Spyre Therapeutics, Inc. | S-1 | 333-276251 | 12/22/2023 | 2.1 | |
| 3.1 | Second Amended and Restated Certificate of Incorporation of the Company, effective as of May 14, 2024 | 8-K | 001-37722 | 05/15/2024 | 3.2 | |
| 3.2 | Amended and Restated Bylaws | S-1/A | 333-276251 | 02/05/2024 | 3.2 | |
| 3.3 | Certificate of Designation of Series A Non-Voting Convertible Preferred Stock | S-1 | 333-276251 | 12/22/2023 | 3.3 | |
| 3.4 | Certificate of Designation of Series B Non-Voting Convertible Preferred Stock | S-1 | 333-276251 | 12/22/2023 | 3.4 | |
| 3.5 | Certificate of Amendment to Certificate of Designation of Series B Non-Voting Convertible Preferred Stock | 8-K | 001-37722 | 03/18/2024 | 3.2 | |
| 10.1# | IL-23 (SPY003) License Agreement, dated October 11, 2024, by and between the Company and Paragon Therapeutics, Inc. | 8-K | 001-37722 | 10/15/2024 | 10.1 | |
| 10.2# | Amended and Restated Biologics Master Services Agreement, dated October 14, 2024, by and between the Company and WuXi Biologics (Hong Kong) Limited. | 8-K | 001-37722 | 10/15/2024 | 10.2 | |
| 10.3# | Amended and Restated Cell Line License Agreement, dated October 14, 2024, by and between the Company and WuXi Biologics (Hong Kong) Limited. | 8-K | 001-37722 | 10/15/2024 | 10.3 | |
| 10.4+ | Fifth Amendment to the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan | X | ||||
| 10.5+ | Offer Letter, dated September 20, 2024, by and between the Company and Sheldon Sloan | X | ||||
| 10.6 | Sales Agreement, dated September 6, 2024, between Spyre Therapeutics, Inc. and TD Securities (USA) LLC | S-3 | 333-281975 | 9/6/2024 | 1.2 | |
| 31.1 | Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934 | X | ||||
| 31.2 | Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934 | X | ||||
| ExhibitNumber | Description | Form | File No | Date of Filing | ExhibitNo. | FiledHerewith |
| 32.1(1) | Certification of the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | X | ||||
| 101.INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | X | ||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | X | ||||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | X | ||||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | X | ||||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | X | ||||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | X | ||||
| 104 | The cover page from this Quarterly Report formatted in Inline XBRL and contained in Exhibit 101 | |||||
- Indicates management contract or compensatory plan.
Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.
(1)The certifications on Exhibit 32 hereto are deemed furnished and not “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that Section. Such certifications will not be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.